RIGVIR

RIGVIR is a virotherapy medication approved by the State Agency of Medicines of the Republic of Latvia.[1] It was developed in the 1960s and 1970s by the team of Aina Muceniece (1924–2010) and patented in 2002.[2]

Virions of enteroviruses in Rigvir

Rigvir is a drug that contains live, natural virus, which has cytolytic and immunomodulating effects. Cytolytic action – finding and destroying malignant cells, applies only to the cancer cells without affecting the normal tissue cells. Regarding immunomodulation, because of its structure Rigvir selectively affects cells in sensitive tumors. Rigvir activates cells of the immune system due to what causes specific immune response against itself. It is not genetically modified and not pathogenic virus, it is not able to replicate in human body. It is issued in oncology for the prevention of secondary immunodeficiency. In 2015 RIGVIR was registered in Georgia[3] and included in the Latvian national guidelines for skin cancer and melanoma treatment.

Recent retrospective study published in Melanoma Research showed that IB-IIC melanoma patients treated with oncolytic virus Rigvir were 4.39–6.57-fold lower mortality than those, who according to melanoma treatment guidelines did not receive virotherapy and were only observed.[4]

Passed all phases of clinical trials and registered in Latvia (Reg. No.: 04-0229) and is used as a prescription drug for the treatment of cancer. Rigvir – 7 strain ECHO-virus, a solution for intramuscular injection. Code: ATX: L03AX. Must be stored and transported at a temperature of -20 °C ± 2 °C.

History

Rigvir antigen in tumor cells

Side effects

Like other medicines, Rigvir may cause side effects. The side effects are short-term and do not require special therapy, the most common side effects are subfebrile temperature, pain in the tumor, fatigue, drowsiness, dyspepsia (diarrhea).[8]

See also

References

  1. For an freely accessible English version see page 642 of Chumakov PM, Morozova VV, Babkin IV, Baikov IK, Netesov SV, Tikunova NV (2012). "Oncolytic enteroviruses" (PDF). Molecular Biology 46 (5): 639–50. doi:10.1134/S0026893312050032.
    For the original version in Russian see Chumakov PM, Morozova VV, Babkin IV, Baĭkov IK, Netesov SV, Tikunova NV (2012). "[Oncolytic enteroviruses] (Russian).". Molekulyarnaya Biologiya 46 (5): 712–25. PMID 23156670.
  2. "Inventions and Inventors of Latvia". Retrieved 8 April 2013.
  3. 1 2 "Georgia Today".
  4. Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurģis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina (2015). "Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study". Melanoma Research 25 (5): 421–426. doi:10.1097/CMR.0000000000000180.
  5. . Muceniece A.J. 1978. Analysis of sensitivity of human melanomas to enteroviruses adaptred to these tumors.In: Virusy v terapii opukholei (Viruses in Antitumor Therapy), Riga: Zinatne, pp. 175–189.
  6. Muceniece A.J., Bumbieris J.V. 1982. Transplantation antigens and their changes in carcinogenesis and viral infection. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, pp. 217–234.
  7. Muceniece A.J., Bumbieris J.V. 1982. Transplantation antigens and their changes in carcinogenesis and viral infection. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, pp. 217–234
  8. "RIGVIR side effects".

External links

This article is issued from Wikipedia - version of the Saturday, February 20, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.